Seroprevalence of varicella-zoster virus antibody and immunogenicity of live attenuated varicella vaccine in healthcare workers in Taiwan

被引:5
|
作者
Chong, Chen Hui [1 ]
Liu, Chun-Eng [1 ,2 ]
Leong, Yin-Yee [3 ]
Liao, Siang-Ying [2 ]
Lai, Huei-Wen [2 ]
Lee, Yu-Lin [1 ,2 ,4 ]
机构
[1] Changhua Christian Hosp, Dept Infect Dis, Changhua, Taiwan
[2] Changhua Christian Hosp, Dept Infect Control, Changhua, Taiwan
[3] Feng Chia Univ, Dept Risk Management & Insurance, Taichung, Taiwan
[4] Changhua Christian Hosp, Dept Infect Dis, 135,Nanxiao St, Changhua 500, Changhua County, Taiwan
关键词
Vaccination; Seroresponse; Seroconversion; Seroreversion; Nosocomial infection; HERPES-ZOSTER; IMMUNITY; OBESITY; EPIDEMIOLOGY; CHICKENPOX; INFECTION; OUTBREAK; TITERS; ADULTS;
D O I
10.1016/j.jmii.2022.09.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Healthcare workers (HCWs) without evidence of immunity to varicella-zoster virus (VZV) are recommended to undergo varicella vaccination. Immunogenicity of live attenuated varicella vaccine has rarely been investigated among HCWs in Taiwan. Methods: Anti-VZV immunoglobulin G (IgG) titer was checked for all HCWs at Changhua Christian Hospital from 2011 to 2017. One-dose and two-dose (separated by 4-8 weeks) vaccines were administered to HCWs with equivocal and negative anti-varicella IgG results, respectively. Follow-up anti-VZV IgG was determined at least 4 weeks after completion of vaccination. Factors associated with seroconversion to varicella vaccination were analyzed. Results: Among 2406 included HCWs, the anti-VZV IgG serostatus was tested positive, equivocal and negative in 1924 (79.9%), 117 (4.9%) and 365 (15.2%), respectively. The seroprevalence had decreased from 88.0% (235/267) in 2011 to 72.2% (270/374) in 2017 (p for trend <0.05). A total of 67.8% (327/482) HCWs completed scheduled vaccination and serological follow-up. The seroconversion rates for HCWs with baseline equivocal and negative anti-VZV IgG results were 100% (80/80) and 79.4% (196/247) after one- and two-dose vaccination, respectively. In multivariate analysis, obesity (adjusted odds ratio, 0.308; 95% confidence interval [CI], 0.11-0.94, p Z 0.039) was the only factor statistically significantly associated with seroconversion to vaccination. Conclusion: Decreasing trends of seroprevalence of VZV were observed among HCWs from 2011 to 2017. HCWs who were obese were less likely to respond to varicella vaccination.
引用
收藏
页码:274 / 281
页数:8
相关论文
共 50 条
  • [41] Live attenuated varicella vaccine for prevention of herpes zoster
    Gershon, A
    Silverstein, S
    BIOLOGICALS, 1997, 25 (02) : 227 - 230
  • [42] Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults
    Weinberg, Adriana
    Canniff, Jennifer
    Rouphael, Nadine
    Mehta, Aneesh
    Mulligan, Mark
    Whitaker, Jennifer A.
    Levin, Myron J.
    JOURNAL OF IMMUNOLOGY, 2017, 199 (02): : 604 - 612
  • [43] Seroprevalence and force of infection of varicella-zoster virus in Luxembourg
    Mossong, J
    Putz, L
    Schneider, F
    EPIDEMIOLOGY AND INFECTION, 2004, 132 (06): : 1121 - 1127
  • [44] Varicella-Zoster Virus Vaccine: Molecular Genetics
    Schmid, D. Scott
    VARICELLA-ZOSTER VIRUS, 2010, 342 : 323 - 340
  • [45] VARICELLA-ZOSTER VIRUS
    DAVISON, AJ
    JOURNAL OF GENERAL VIROLOGY, 1991, 72 : 475 - 486
  • [46] Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection
    Wen-Bo Zeng
    Fukun Zhang
    Shuang Cheng
    Jin-yan Sun
    Hongjie Shen
    Min-Hua Luo
    Virologica Sinica, 2021, 36 (01) : 159 - 162
  • [47] Upregulation of keratin 15 is required for varicella-zoster virus replication in keratinocytes and is attenuated in the live attenuated vOka vaccine strain
    Tommasi, Cristina
    Yogev, Ohad
    Yee, Michael B.
    Drousioti, Andriani
    Jones, Meleri
    Ring, Alice
    Singh, Manuraj
    Dry, Inga
    Atkins, Oscar
    Naeem, Aishath S.
    Kriplani, Nisha
    Akbar, Arne N.
    Haas, Juergen G.
    O'Toole, Edel A.
    Kinchington, Paul R.
    Breuer, Judith
    VIROLOGY JOURNAL, 2024, 21 (01)
  • [48] VARICELLA-ZOSTER VIRUS VACCINE, SUCCESSES AND DIFFICULTIES
    Sarkadi, Julia
    ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, 2013, 60 (04) : 379 - 396
  • [49] Varicella-zoster virus
    Arvin, AM
    CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (03) : 361 - +
  • [50] Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease
    McAdam, Lawrence
    Eberhardson, Michael
    Grainger, William
    Papp, Kim
    Hall, Stephen
    Sterling, Tina
    Stek, Jon
    Pang, Lei
    Zhao, Yanli
    Chan, Ivan
    Haupt, Richard
    Parrino, Janie
    Silber, Jeffrey
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3327 - 3327